← back to search

Dan Turner

Oxford Nanopore Technologies (United Kingdom) · IL
Area of research
Genetics · Epidemiology
Research interest
Research interests include Inflammatory Bowel Disease, Microscopic Colitis, HIV Research and Treatment, and HIV/AIDS drug development and treatment.
h-index
80
citations
42,248
works
617
NIH funding
primary concept
Medicine
email

Recent publications

Management of pediatric inflammatory bowel diseases in limited‐resource settings: A position paper from the Paediatric IBD Porto Group of ESPGHAN
Journal of Pediatric Gastroenterology and Nutrition 2025cited by 5position: middledoi
Metabolomics reveal distinct molecular pathways associated with future risk of Crohn’s Disease
Gut Microbes 2025cited by 3position: middledoi
Real-World Experience with Upadacitinib for Pediatric Acute Severe Ulcerative Colitis: An International Multicenter Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN
Inflammatory Bowel Diseases 2025cited by 2position: middledoi
Drug resistance testing at regimen failure in individuals diagnosed with HIV-1 between 2010 and 2018 in Israel
AIDS 2025cited by 1position: middledoi
Machine learning for predicting Crohn’s disease from routine blood tests years before diagnosis: results from the epi-IIRN cohort
Journal of Crohn s and Colitis 2025cited by 1position: middledoi
Environmental Factors Associated With Risk of Crohn’s Disease Development in the Crohn’s and Colitis Canada - Genetic, Environmental, Microbial Project
Clinical Gastroenterology and Hepatology 2024cited by 28position: middledoi
Early Initiation of Biologics and Disease Outcomes in Adults and Children With Inflammatory Bowel Diseases: Results From the Epidemiology Group of the Nationwide Israeli Inflammatory Bowel Disease Research Nucleus Cohort
Gastroenterology 2024cited by 25position: lastdoi
Healthy First-Degree Relatives From Multiplex Families vs Simplex Families Have Higher Subclinical Intestinal Inflammation, a Distinct Fecal Microbial Signature, and Harbor a Higher Risk of Developing Crohn’s Disease
Gastroenterology 2024cited by 20position: middledoi
Durability of Adalimumab and Infliximab in Children With Crohn’s Disease: A Nationwide Comparison From the epi-IIRN Cohort
Inflammatory Bowel Diseases 2024cited by 13position: lastdoi
Upadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multicenter Study
Journal of Crohn s and Colitis 2024cited by 13position: middledoi
Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: UniStar study long‐term extension results
Journal of Pediatric Gastroenterology and Nutrition 2024cited by 11position: firstdoi
Durability of the First Biologic in Children and Adults With Ulcerative Colitis: A Nationwide Study from the epi-IIRN
Inflammatory Bowel Diseases 2024cited by 9position: lastdoi
Predictors of Complicated Disease Course in Adults and Children With Crohn’s Disease: A Nationwide Study from the epi-IIRN
Inflammatory Bowel Diseases 2024cited by 8position: lastdoi
The Epidemiology of Inflammatory Bowel Diseases During the COVID-19 Pandemic: Comparison of Two Nationwide Cohorts
Journal of Crohn s and Colitis 2024cited by 7position: middledoi
Predictors of Complicated Disease Course in Children and Adults With Ulcerative Colitis: A Nationwide Study From the epi-IIRN
Inflammatory Bowel Diseases 2024cited by 7position: lastdoi
P775 Efficacy and safety of risankizumab in children with Crohn’s disease: A preliminary report
Journal of Crohn s and Colitis 2024cited by 5position: middledoi
Serum Metabolites Relate to Mucosal and Transmural Inflammation in Paediatric Crohn Disease
Journal of Crohn s and Colitis 2024cited by 4position: middledoi
Familial Mediterranean fever in patients with inflammatory bowel diseases: a nationwide study from the epi-IIRN
Lara D. Veeken 2024cited by 3position: middledoi
Outcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-onset and Adult-onset Disease
Journal of Crohn s and Colitis 2024cited by 2position: middledoi
Serological Markers as Predictors of Anti-TNF Response in Children with Crohn’s Disease
Digestive Diseases and Sciences 2024cited by 2position: middledoi
Mpox in people with past infection or a complete vaccination course: a global case series
The Lancet Infectious Diseases 2023cited by 139position: middledoi
Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting
˜The œLancet. Gastroenterology & hepatology 2023cited by 117position: middledoi
Anti-Integrin αvβ6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative Colitis
Gastroenterology 2023cited by 86position: middledoi
Immune response and barrier dysfunction-related proteomic signatures in preclinical phase of Crohn’s disease highlight earliest events of pathogenesis
Gut 2023cited by 71position: middledoi
Precision medicine in monogenic inflammatory bowel disease: proposed mIBD REPORT standards
Nature Reviews Gastroenterology & Hepatology 2023cited by 20position: middledoi
5‐aminosalicylate maintenance is not superior to no maintenance in patients with newly diagnosed Crohn's disease—A nationwide cohort study
Alimentary Pharmacology & Therapeutics 2023cited by 18position: middledoi
Validation of predictive models for disease outcomes in paediatric ulcerative colitis: A multicentre prospective inception cohort
Alimentary Pharmacology & Therapeutics 2023cited by 11position: middledoi
Outcome of Very Early Onset Inflammatory Bowel Disease Associated With Primary Sclerosing Cholangitis: A Multicenter Study From the Pediatric IBD Porto Group of ESPGHAN
Inflammatory Bowel Diseases 2023cited by 11position: middledoi
Prevalence and Outcomes of No Treatment Versus 5-ASA in Ulcerative Colitis: A Nationwide Analysis From the epi-IIRN
Inflammatory Bowel Diseases 2023cited by 10position: lastdoi
Outcomes and Endpoints of Postoperative Recurrence in Crohn’s Disease: Systematic Review and Consensus Conference
Journal of Crohn s and Colitis 2023cited by 9position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Anne M. Griffiths · SickKids Foundation41 papers (2012–2025)Frank M. Ruemmele · Biodiversité et Biotechnologie Fongiques31 papers (2013–2023)Oren Ledder · Hebrew University of Jerusalem30 papers (2012–2024)Iris Dotan · Tel Aviv University29 papers (2017–2025)Gili Focht · Hebrew University of Jerusalem28 papers (2016–2024)Lissy de Ridder · Erasmus MC - Sophia Children’s Hospital28 papers (2012–2025)Arie Levine · Wolfson Medical Center27 papers (2012–2021)Richard K. Russell · Centre for Inflammation Research25 papers (2012–2022)Eran Matz · Atrium Health Wake Forest Baptist22 papers (2017–2025)Jeffrey S. Hyams · S.P.E.C.I.E.S.21 papers (2013–2024)Ron Shaoul · Technion – Israel Institute of Technology21 papers (2012–2023)Ohad Atia · Hebrew University of Jerusalem20 papers (2019–2024)Amit Assa · Hebrew University of Jerusalem18 papers (2017–2025)Marina Aloi · Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau17 papers (2014–2025)Raffi Lev‐Tzion · Hebrew University of Jerusalem17 papers (2012–2025) · 16 papers (2012–2019)Sibylle Koletzko · München Klinik16 papers (2012–2024) · 15 papers (2021–2024)Revital Kariv · Hebrew University of Jerusalem14 papers (2020–2024)Jorge Amil Dias · Lusíada University of Porto14 papers (2012–2025)